Glimulin MV 2 Tablet ER is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), formulated for extended-release administration. This synergistic formulation is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, attenuating postprandial hyperglycemia. The extended-release formulation ensures a sustained therapeutic effect, improving patient compliance by reducing dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glimulin MV 2 Tablet ER should be used as part of a comprehensive diabetes management plan, including diet and exercise. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. This combination therapy offers a multifaceted approach to glycemic control, targeting fasting and postprandial glucose levels effectively.

Dosage & How to Use